A large national study is being conducted on an Alzheimer's drug candidate, and Atlanta-based NeuroTrials Research Inc. is the only trial site in Georgia currently enrolling patients. Dr. Michael Lacey serves as the study's primary investigator.
NeuroTrials is one of 50 locations across the United States participating in the NOBLE Study, a Phase-2 randomized, double blind, placebo controlled study on the potential of T-817MA, a neuroprotectant agent designed to protect against neuron loss. Neuroprotectants are used for central nervous system disorders including stroke and Parkinson's disease, but the NOBLE study is focusing on men and women with mild to moderate Alzheimer's disease.
Participants will be treated for about 14 months. For more information on the study & to see if someone you know may qualify, visit our study page.
Other trial sites include Georgetown University, Mount Sinai School of Medicine, Princeton University's Medical Institute and Columbia University.
Read the full article.